ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. - Wikidata - wikimedia - TriplyDB

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

http://www.wikidata.org/entity/Q37508792

about

Loss of MutL Disrupts Chk2-dependent Cell Cycle Control Through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.Marked for death: targeting epigenetic changes in cancer.Targeting the ATR-CHK1 Axis in Cancer Therapy Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities.Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.ARID1A mutation in blastic plasmacytoid dendritic cell neoplasm.Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability.Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer - Early Results from the COMPASS Trial.The diagnostic role of PTEN and ARID1A in serous effusions.ATR Is a Therapeutic Target in Synovial Sarcoma.Directing the use of DDR kinase inhibitors in cancer treatment.Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.The HNF-1β-USP28-Claspin pathway upregulates DNA damage-induced Chk1 activation in ovarian clear cell carcinoma.The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression.ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells

P2860

Q38628334-D4DDC6B3-7490-44E8-856F-340D1F929B2B Q38747872-6B69AFFB-2125-4E7B-86E4-D65D341E8FFB Q38817102-995BDAB1-50AA-4DF9-9D2D-E331552E989F Q39229171-5E34C4E6-7CD5-4F24-865A-770CE665724B Q47122646-AA2C1818-C5DC-4AB9-8755-719D1E6779A1 Q47161485-A7AC782C-1021-4F97-A1D1-67F3187C37FF Q47164606-B073352D-1886-40ED-AE18-929B31FC592F Q47232401-D70C732D-0572-4795-B02E-46B4CC0792F6 Q47369086-5708D77A-3117-44A5-9E7F-3291C864DF89 Q47643551-8D9489DD-4E0C-425E-ABEB-4F87B3B85002 Q47687840-06121A6B-C005-4710-9C08-982FCEEF5E3F Q49679908-5B220B9C-CA13-40D9-901A-45B0B8519667 Q52586328-1865A81E-ADCA-4B1D-AE3F-69D088A02486 Q52715782-3D1D5C47-21D9-4F8E-B5E8-F9A8BA504317 Q54976514-4C7E4CE7-AD54-4880-B2CF-91DB5D043F03 Q54977196-77E91F55-F7DC-4A9F-87A4-2D33F12AF0DE Q55104265-62576DB5-5404-4139-B2C8-DBBF7ACEFCBB Q55710290-51BCB10B-AED4-4451-8406-18D4FA5C3EAA Q57176137-54B306D9-31C1-4D7A-94F9-E173C71DB8CA Q58790921-944CCFF9-2FB8-409D-AF44-4678604002CE

P2860

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

http://www.wikidata.org/entity/Q37508792

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

@en

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

@nl

type

label

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

@en

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

@nl

prefLabel

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

@en

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

@nl

P1433

Q37508792-EBED977A-AC7E-41CB-BCA5-41D3D707C31D

P1476

Q37508792-57A893DC-41E6-424E-9BB8-E3CB8D628645

P2093

Q37508792-1A392B4A-9E90-4638-9142-047F8F350230

Q37508792-1BAF024D-A131-4A81-8618-B8EA540998FE

Q37508792-26134DCA-B62E-48C1-ABCD-FEB46BF9F478

Q37508792-30DF730E-B4E2-430F-8A9E-3EC8A63B14F4

Q37508792-48D4E675-3276-4926-9B38-422F052EF54A

Q37508792-55817EB6-1139-4949-BBE2-550F74631D12

Q37508792-8E6A55F6-9D4D-4B29-9A7B-465FEFDFF962

Q37508792-8F65A4D0-DF8F-4126-9D4D-04E7CD9BFCB0

Q37508792-94117F89-8386-4106-B5D3-E1E2C66F447E

Q37508792-9BD007F5-0AC3-430A-AB1A-A1849C2EC736

P2860

Q37508792-03D7C9CA-C4AA-43BF-86FB-91C3B20BC90E

Q37508792-0A9541DD-66E7-472C-8AFD-CFA03C8F7ACB

Q37508792-1139C6AA-FE58-4CCA-B141-3681291F9872

Q37508792-152D3DC6-C36B-4464-8D6D-5297623FE61F

Q37508792-17DF128D-5C11-400E-B833-4AC7D40162A6

Q37508792-190BC241-89CB-4EDD-AB3B-C52CD9C7B996

Q37508792-19DAFC84-33E6-40F3-9972-E69F21B1B46B

Q37508792-1A4BA626-05CF-4B57-A570-5A0D39380D7A

Q37508792-1A51D84D-BF63-4049-8D1D-01E8C3122C17

Q37508792-1CB3C28E-E159-4901-B41D-00B2FEB45DB1

P2888

Q37508792-FE3ADB47-CFB5-4DEC-BC4E-C774B1F27823

P304

Q37508792-CEC56151-E74D-4037-8F38-1D4FCAB099B4

P31

Q37508792-DE085085-811C-4ECA-8487-0C7B30E5F831

P356

Q37508792-AAF6C6DF-B7C5-4E29-AB8D-5B3548C27DD7

P407

Q37508792-968102BA-8FD9-4793-9EB4-6A28184D81A9

P478

Q37508792-0A1FD111-0D0D-4E92-8A32-33A09F70DEB7

P50

Q37508792-1C3C0049-0374-49EE-8300-2D673A7F3AA2

Q37508792-2F5587BA-5699-4F7B-8394-1F6CC28D6411

Q37508792-392DF9C8-8150-4012-A044-879F07022D8E

Q37508792-54F64D56-AD71-4ABD-BB3D-66CFCF95F48B

P577

Q37508792-B4309998-A7D8-41F1-BD9F-2C3E9698D82C

P698

Q37508792-9346894B-5FC3-49C8-884E-813F5786722B

P932

Q37508792-6D0E7A7B-6ECE-4BB1-9369-68B3497FEB80

P356

P1433

Nature Communications

P1476

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

@en

P2093

Aditi Gulati

http://www.w3.org/2001/XMLSchema#string

Andrew R Reynolds

http://www.w3.org/2001/XMLSchema#string

Asha Konde

http://www.w3.org/2001/XMLSchema#string

Chris T Williamson

http://www.w3.org/2001/XMLSchema#string

Helen N Pemberton

http://www.w3.org/2001/XMLSchema#string

James Campbell

http://www.w3.org/2001/XMLSchema#string

John R Pollard

http://www.w3.org/2001/XMLSchema#string

Nicholas Badham

http://www.w3.org/2001/XMLSchema#string

Peter B Vermulen

http://www.w3.org/2001/XMLSchema#string

Philip M Reaper

http://www.w3.org/2001/XMLSchema#string

P2860

DNA T OPOISOMERASES : Structure, Function, and Mechanism

Two related ARID family proteins are alternative subunits of human SWI/SNF complexes

A census of human cancer genes

Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes

SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability

Chemical strategies for development of ATR inhibitors

Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis

ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a

Cisplatin: mode of cytotoxic action and molecular basis of resistance

DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma

P2888

P304

13837

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS13837

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Christopher J Lord

Jeffrey C Francis

P577

2016-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27958275

http://www.w3.org/2001/XMLSchema#string

P932

5159945

http://www.w3.org/2001/XMLSchema#string